Dr.GAURANG SEHGAL

Dr.PREMPAL KAUR, Dr.Karamjit Singh

Abstract

Purpose: Vaso endothelial growth factor (VEGF), a glycoprotein secreted by vascular endothelial cells is a novel biomarkers related to pathogenesis of onset and progression of DR.

Methods and Materials: 180 consecutive diabetic patients 180 healthy matched controls were taken. Based on the early treatment of diabetic retinopathy study (ETDRS), patients were classified. Serum VEGF values by ELISA and Central Macular thickness were evaluated

Results: Serum VEGF levels showed an incremental trend from no DR (275.6 ± 28.60pg/ml) to mild NPDR (298 ± 22.2pg/ml) ,moderate NPDR(301 ± 24.6pg/ml), severe NPDR(310 ± 28.5pg/ml) to PDR group(356.6 ± 58.1 pg/ml) with NPDR/PDR with CSME (395.2 ± 21.5pg/ml)

CMT showed an incremental rise from no DR(210.26±36.3μm)to NPDR(222 ± 22.65μm) to PDR(279 ± 31.60μm) and to NPDR/PDR with CSME (356 ± 30.51μm). It had positive correlation with serum VEGF

Conclusion: Serum VEGF can be used as biomarker in areas with scarcity of ophthalmologists.

Full Text